The post Hyperliquid Price Surges 21% After HIP-4 Outcome Trading Update; 30% Upside in Focus appeared first on Coinpedia Fintech News The broader crypto marketThe post Hyperliquid Price Surges 21% After HIP-4 Outcome Trading Update; 30% Upside in Focus appeared first on Coinpedia Fintech News The broader crypto market

Hyperliquid Price Surges 21% After HIP-4 Outcome Trading Update; 30% Upside in Focus

4 min read
Hyperliquid (HYPE) Price Extends Rally as Silver Futures Trigger Volume Shock

The post Hyperliquid Price Surges 21% After HIP-4 Outcome Trading Update; 30% Upside in Focus appeared first on Coinpedia Fintech News

The broader crypto market is attempting a cautious recovery after the recent sell-off pushed the Bitcoin price below the $75,000 mark. While sentiment across major assets remains mixed, Hyperliquid has moved in the opposite direction, maintaining a strong upward trend and outperforming the wider market.

The divergence comes as Hyperliquid breaks above a key consolidation range following the announcement of a new product update under HIP-4, which expands the platform’s trading capabilities and introduces new on-chain use cases.

HYPE price reacted swiftly to the development, climbing more than 20% on the day. The token moved decisively higher from the $30 consolidation zone to trade above $37.5, signaling renewed bullish momentum. The rally has also pushed Hyperliquid into the top 10 crypto by market capitalization, overtaking Cardano.

Hyperliquid’s HIP-4 Upgrade Renews Market Interest

The price surge followed the unveiling of HIP-4, a proposal that introduces outcome-based trading on Hyperliquid. The upgrade brings prediction market–style instruments and option-like derivatives directly on-chain, marking a significant expansion beyond the platform’s core perpetual futures offering.

According to Hyperliquid, the new product structure allows traders to express market views with predefined risk, without relying on traditional liquidation mechanics. This design is seen as a step toward positioning Hyperliquid as a more comprehensive trading venue rather than a platform focused solely on perpetuals.

The announcement has been well received by the market, with traders increasingly viewing HIP-4 as a milestone in Hyperliquid’s evolution toward a full-spectrum DeFi trading hub.

Why the Update Matters

The HIP-4 upgrade strengthens the longer-term narrative around platform diversification and potential revenue stability. By introducing outcome-based instruments, Hyperliquid opens the door to new liquidity sources and user segments, including more sophisticated traders seeking structured, on-chain exposure.

Market participants are now closely watching whether adoption of the new trading format translates into sustained volume growth and deeper network effects. If participation follows product expansion, demand for HYPE could remain supported beyond the initial reaction.

For now, Hyperliquid’s ability to rally against a fragile market backdrop highlights the impact of protocol-specific catalysts, as traders rotate toward assets showing both technical strength and clear fundamental developments.

Hyperliquid Price Analysis: Will HYPE Reach $50?

As mentioned earlier, HYPE has maintained a strong upward trend, defying broader market sentiment and outperforming several top cryptocurrencies. Despite only a modest rise in trading volume, buying pressure has been strong enough to lift the price out of its consolidation range near $30 and push it above $37.

The move allowed HYPE to break through the key $35–$36 resistance zone. With that level cleared, the token is now testing its next major technical barrier—the 200-day moving average near $38.01. The focus now shifts to whether this resistance can flip into support, a development that could strengthen the bullish structure and open the door for a move toward the $50 level.

hype price

HYPE is finally showing some life after a long corrective phase. Price has bounced strongly from the $28–30 demand zone and is now pushing into the $35–37 resistance area, which earlier acted as a key support before the breakdown. This zone also lines up closely with the 200-day SMA near $38, making it a crucial level to watch. The recent move is backed by better volume and a positive shift in CMF, hinting that buyers are slowly stepping back in, rather than this being a random spike.

If HYPE manages to hold above $35–36, the recovery can extend toward $43 in the near term, followed by a bigger test around $48–50, where strong selling pressure is likely. However, rejection from this zone could send the price back toward $30, and if that fails, $26–28 comes back into focus. Momentum is improving, but the real trend shift only confirms above the 200-day average.

Bottom line: Can the HYPE Price Reach $50 in February 2026?

Hyperliquid’s latest rally has drawn comparisons to the market response following the HIP-3 update, which marked one of the protocol’s earlier major product milestones. After HIP-3 was rolled out, HYPE saw a sustained price expansion, rising from the low-$20 range to above $30 over the following weeks, a move of roughly 40%–45%, supported by rising platform activity and visibility rather than a short-lived speculative spike.

If HIP-4 gains traction similar to HIP-3, increased participation and liquidity could make the current rally more durable rather than just a short-term spike. With this, the possibility of surpassing $50 could be more realistic, paving the way for a new ATH this month. 

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump swears he'll donate winnings in $10 billion lawsuit against his own IRS

Trump swears he'll donate winnings in $10 billion lawsuit against his own IRS

President Donald Trump told NBC News' Tom Llamas in an interview released on Wednesday that he has no interest in actually keeping any money he wins from his lawsuit
Share
Rawstory2026/02/05 10:43
US President Donald Trump says Warsh would’ve lost Fed if he pledged rate hike

US President Donald Trump says Warsh would’ve lost Fed if he pledged rate hike

The post US President Donald Trump says Warsh would’ve lost Fed if he pledged rate hike appeared on BitcoinEthereumNews.com. US President Donald Trump said that
Share
BitcoinEthereumNews2026/02/05 10:23
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11